Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy

He HUANG; Houyu JU; Wenyi YANG; Ming YAN; Guoxin REN; Jingzhou HU

doi:10.19401/j.cnki.1007-3639.2023.06.009

您当前的位置：

首页 >

文章列表页 >

Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy

Article | 更新时间：2025-12-31

- Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy
- China Oncology Vol. 33, Issue 6, Pages: 613-618(2023)
- 作者机构：
  
  上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科，上海交通大学口腔医学院，国家口腔医学中心，国家口腔疾病临床医学研究中心，上海市口腔医学重点实验室，上海市口腔医学研究所，上海 200011
- 作者简介：
  
  HU Jingzhou.
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.06.009
  CLC： R739.91
- Received：16 March 2023，
  
  Revised：2023-06-02，
  
  Published：30 June 2023
- 稿件说明：
移动端阅览
He HUANG, Houyu JU, Wenyi YANG, et al. Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy[J]. China Oncology, 2023, 33(6): 613-618.
DOI：

He HUANG, Houyu JU, Wenyi YANG, et al. Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy[J]. China Oncology, 2023, 33(6): 613-618. DOI： 10.19401/j.cnki.1007-3639.2023.06.009.

摘要

背景与目的：

程序性死亡[蛋白

]

-1（programmed death-1，PD-1）单抗免疫治疗在头颈部鳞状细胞癌（head and neck squamous cell carcinoma，HNSCC）中的作用愈发重要，然而目前具有响应率低、缺乏预测性生物标志物的问题。本研究旨在确定程序性死亡[蛋白

]

配体-2（programmed death ligand-2，PD-L2）能否作为预测HNSCC中PD-1单抗免疫治疗获益情况的生物标志物。

方法：

收集50例接受PD-1单克隆抗体免疫治疗的中晚期HNSCC的组织标本及临床数据，采用免疫组织化学染色法分析程序性死亡[蛋白

]

配体-1（programmed death ligand-1，PD-L1）、PD-L2表达量，采用SPSS 26.0软件根据基本临床特征、PD-L1与PD-L2表达量分组统计并进行Kaplan-Meier生存分析，采用GraphPad Prism软件绘制生存曲线。

结果：

PD-L2在HNSCC患者中阳性表达率较高，有超过80%的患者肿瘤组织可检出PD-L2表达；PD-L2的表达量显著影响免疫治疗结局，PD-L2高表达的患者平均生存期为18.8（16.0 ~ 21.7）个月，而PD-L2低表达的患者平均生存期为11.0（9.1 ~ 12.8）个月，差异有统计学意义（

0.05）。

结论：

PD-L2可作为评估HNSCC中PD-1单克隆抗体免疫治疗获益的生物标志物。

Abstract

Background and purpose:

Programmed death-1 (PD-1) monoclonal antibody therapy plays an increasingly important role in the treatment of head and neck squamous cell carcinoma (HNSCC). However

low response rate and lack of predictive biomarkers are still the challenging problems. This study aimed to confirm that programmed death ligand-2 (PD-L2) is a predictive biomarker for the outcome of HNSCC anti-PD-1 immunotherapy.

Methods:

The samples and clinical data of 50 HNSCC patients undergoing PD-1 monoclonal antibody immunotherapy were collected. Immunohistochemical staining was used to analyze the level of programmed death ligand-1 (PD-L1) and PD-L2. Kaplan-Meier overall survivals were analyzed using SPSS 26.0 software

grouped by the basic clinical characteristics and the PD-L1 and PD-L2 levels. Survival curves were plotted using GraphPad Prism.

Results:

HNSCC had a relatively high expression rate of PD-L2 with more than 80% of cases detected as PD

-L2 positive. The expression of PD-L2 significantly correlated with the clinical outcome of immunotherapy

with a mean survival of 18.8 (16.0-21.7) months for patients with high PD-L2 expression and 11.0 (9.1-12.8) months for patients with low PD-L2 expression

this difference being statistically significant.

Conclusion:

PD-L2 has the potential to be used as a predictive biomarker for HNSCC anti-PD-1 immunotherapy.

关键词

Keywords

references

SIEGEL R L , MILLER K D , WAGLE N S , et al. Cancer statistics, 2023 [J ] . CA Cancer J Clin , 2023 , 73 ( 1 ): 17 - 48 . DOI: 10.3322/caac.v73.1 http://doi.org/10.3322/caac.v73.1 https://onlinelibrary.wiley.com/toc/15424863/73/1 https://onlinelibrary.wiley.com/toc/15424863/73/1

KEAM B , MACHIELS J P , KIM H R , et al. Pan-Asian adaptation of the EHNS-ESMO-ESTRO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck [J ] . ESMO Open , 2021 , 6 ( 6 ): 100309 . DOI: 10.1016/j.esmoop.2021.100309 http://doi.org/10.1016/j.esmoop.2021.100309 https://linkinghub.elsevier.com/retrieve/pii/S2059702921002714 https://linkinghub.elsevier.com/retrieve/pii/S2059702921002714

LICITRA L , FELIP E , GUIDELINES WORKING GROUP E O. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2009 , 20 ( Suppl 4 ): 121 - 122 . DOI: 10.1093/annonc/mdn551 http://doi.org/10.1093/annonc/mdn551 https://linkinghub.elsevier.com/retrieve/pii/S0923753419399636 https://linkinghub.elsevier.com/retrieve/pii/S0923753419399636

SHARMA P , ALLISON J P . The future of immune checkpoint therapy [J ] . Science , 2015 , 348 ( 6230 ): 56 - 61 . DOI: 10.1126/science.aaa8172 http://doi.org/10.1126/science.aaa8172

FERRIS R L , BLUMENSCHEIN G Jr , FAYETTE J , et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck [J ] . N Engl J Med , 2016 , 375 ( 19 ): 1856 - 1867 . DOI: 10.1056/NEJMoa1602252 http://doi.org/10.1056/NEJMoa1602252 http://www.nejm.org/doi/10.1056/NEJMoa1602252 http://www.nejm.org/doi/10.1056/NEJMoa1602252

NCCN . NCCN clinical practice guidelines in oncology: head and neck cancers [EB/OL ] . Version 1.2023 . [ 2023-03-15 ] . https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437 https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437 https://www.nccn.org/guidelines/guidelines-detail?category=1 & id=1437.

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会(CSCO)免疫检查点抑制剂临床应用指南-2022 [M ] . 北京 : 人民卫生出版社 , 2022 .

Guide Working Committee of the Chinese Society of Clinical Oncology . Guidelines of Chinese Society of Clinical Oncology (CSCO) immune checkpoint inhibitor clinical practice-2022 [M ] . People's Medical Publishing House, Beijing , 2022 .

COHEN E E W , SOULIÈRES D , LE TOURNEAU C , et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study [J ] . Lancet , 2019 , 393 ( 10167 ): 156 - 167 . DOI: S0140-6736(18)31999-8 http://doi.org/S0140-6736(18)31999-8

DESILETS A , SOULIÈRES D . Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma [J ] . Expert Opin Drug Saf , 2020 , 19 ( 8 ): 927 - 934 . DOI: 10.1080/14740338.2020.1775811 http://doi.org/10.1080/14740338.2020.1775811

LATCHMAN Y , WOOD C R , CHERNOVA T , et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation [J ] . Nat Immunol , 2001 , 2 ( 3 ): 261 - 268 . DOI: 10.1038/85330 http://doi.org/10.1038/85330

BAGCHI S , YUAN R , ENGLEMAN E G . Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance [J ] . Annu Rev Pathol , 2021 , 16 : 223 - 249 . DOI: 10.1146/annurev-pathol-042020-042741 http://doi.org/10.1146/annurev-pathol-042020-042741

YEARLEY J H , GIBSON C , YU N , et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer [J ] . Clin Cancer Res , 2017 , 23 ( 12 ): 3158 - 3167 . DOI: 10.1158/1078-0432.CCR-16-1761 http://doi.org/10.1158/1078-0432.CCR-16-1761

WANG W L , ADEOYE J , THOMSON P , et al. Statistical profiling of oral cancer and the prediction of outcome [J ] . J Oral Pathol Med , 2021 , 50 ( 1 ): 39 - 46 . DOI: 10.1111/jop.v50.1 http://doi.org/10.1111/jop.v50.1 https://onlinelibrary.wiley.com/toc/16000714/50/1 https://onlinelibrary.wiley.com/toc/16000714/50/1

Views

986

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Research status and progress of third-line treatment for metastatic colorectal cancer

The ten-year evolution of systemic therapy for advanced differentiated thyroid cancer: a comparison between the 2015 and 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer

Related Author

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

GAO Hongsheng

ZHANG Ruixing

Hao LIU

Junjie SU

Related Institution

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

Committee of Head and Neck Cancer, Chinese Society of Clinical Oncology

AI问答

⁰